Previous 10 | Next 10 |
Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q2 2022 Earnings Call Transcript
Agile Therapeutics, Inc. (AGRX) Q2 2022 Results Conference Call August 11, 2022 04:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing Conference Call Participants Oren Livnat - H.C. Wainright ...
Agile Therapeutics press release ( NASDAQ: AGRX ): Q2 GAAP EPS of -$2.71 beats by $0.99 . Revenue of $2.1M (+75.0% Y/Y) beats by $0.12M . “Our goals as a company are to grow our Twirla brand and become cash flow positive. We believe we took important ste...
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla ® Product Supply Agreement with Nurx Management to Host Conference ...
PRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market close on Thursday, August 11, 2022. Following the release, the Company wi...
Today, we revisit a small biopharma called Agile Therapeutics for the first time in a year and a half. The company recently addressed its short-term funding needs, and its Twirla contraception patch seems to be gaining some traction. An investment analysis follows in the paragraph...
Agile Therapeutics ( NASDAQ: AGRX ) updated its Q2 Twirla demand (total cycles) and operating expense guidance that was initially provided on May 24, 2022. Twirla demand is now seen to be at the mid-point of the earlier provided range (20K to 22K) of 21K to 21.5K...
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range Operating Expenses (OPEX) Expected to be Below Guided Range PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company,...
Agile Therapeutics ( NASDAQ: AGRX ) rose sharply in the early trading on Monday after H.C. Wainwright doubled the price target on the women's healthcare company to a Street high of $5.00 citing its prospects following the recent Supreme Court ruling on abortion rights. ...
Penny Stocks To Buy If you want to make money in the stock market today and do it quickly, penny stocks might be on your watch list. According to the definition, we’re talking about stocks trading below $5. But for some, they look for much cheaper stocks to buy. Penny Stocks ...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 ...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...